The goals of the core are to provide all projects with centralized leadership and administrative support, and to ensure effective communication among all projects and cores so that translational objectives are being met. To achieve this goal the core will arrange internal group meetings including the monthly investigator meeting, executive committee meetings and invited research lectures. It will oversee the overall fiscal and budgetary management of the SPORE and provide assistance to each project and core leader, with a particular focus on assisting budgetary planning for clinical translation. The Core will also use its discretionary funds to support new research opportunities or unexpected costs. During the initial funding period, this core has monitored each project with input from the Executive Committee and Advisory Board, and modified projects and incorporated new directions as necessary. For the current proposal. Administrative Core leaders will ensure continued SPORE oversight by convening meetings of the Internal and Advisory Boards and assessing and implementing their recommendations. The activities of the Career Development and the Developmental Research Programs will both be co-ordinated with other SPORE activities through this Administrative Core to ensure that the objectives of these programs are being met. Finally the Administrative Core will communicate with the NCI SPORE program Staff and encourage and facilitate collaboration with other SPORES and networks.
The Administrative Core supports the leadership of all SPORE projects and cores and integrates these with the Career Development and Developmental Research Programs. It organizes meetings to monitor progress and promote collaboration and identifies new research opportunities.
|Iwahori, Kota; Kakarla, Sunitha; Velasquez, Mireya P et al. (2015) Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 23:171-8|
|Ngo, Minhtran Charlotte; Ando, Jun; Leen, Ann M et al. (2014) Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother 37:193-203|
|Ok, Chi Young; Li, Ling; Xu-Monette, Zijun Y et al. (2014) Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 20:2338-49|
|Bollard, Catherine M; Gottschalk, Stephen; Torrano, Vicky et al. (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32:798-808|
|Rouce, Rayne H; Louis, Chrystal U; Heslop, Helen E (2014) Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol 21:476-81|
|Leen, Ann M; Heslop, Helen E; Brenner, Malcolm K (2014) Antiviral T-cell therapy. Immunol Rev 258:12-29|
|Xu, Xin; Hegazy, Wael A H; Guo, Linjie et al. (2014) Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer Res 74:6260-70|
|Zhou, Xiaoou; Di Stasi, Antonio; Tey, Siok-Keen et al. (2014) Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123:3895-905|
|Papadopoulou, Anastasia; Krance, Robert A; Allen, Carl E et al. (2014) Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther 22:1134-8|
|Anurathapan, Usanarat; Leen, Ann M; Brenner, Malcolm K et al. (2014) Engineered T cells for cancer treatment. Cytotherapy 16:713-33|
Showing the most recent 10 out of 121 publications